Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.”In the company’s words, NCT04135417 on ClinicalTrials.gov
- Tested for
- Renal Failure, End Stage Renal Disease, Vascular Access, Hemodialysis
- Main trialPhase 2
- “This is a Phase 2, prospective, multicenter, open-label, single-arm study of the Human Acellular Vessel (HAV).”In the company’s words, NCT04135417 on ClinicalTrials.gov
Other drugs for Renal Failure
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- QRX-3Ebima Clifford Okundaye · Phase 2/3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- Migalastat HClAmicus Therapeutics · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 15 May 2021 | Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026